KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.85

Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).

Ji Hyun Kim, Sung-Youn Chun, Dong-Eun Lee, Yo Han Woo, Suk-Joon Chang, Sang-Yoon Park, Yoon Jung Chang, Myong Cheol Lim

Gynecol Oncol 170 19-24

PMID36608383
PMCID-
DOI10.1016/j.ygyno.2022.12.021
发表日期2023-01-06
入排依据:The record is an economic evaluation derived from a phase III RCT but does not report direct oncology efficacy outcomes (e.g., survival, progression) required for inclusion in this cohort.
摘要

摘要

BACKGROUND: To evaluate the cost-effectiveness of the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) following interval cytoreductive surgery (ICS) for stage III-IV ovarian cancer from a randomized controlled phase III trial. METHODS: A comparative cost-effective analysis was performed using a Markov health-state transition model derived from the current trial cohort (ClinicalTrials.gov Identifier: NCT01091636). The incremental cost-effectiveness ratio (ICER) was evaluated by dividing the incremental costs by incremental quality-adjusted life-years (QALYs) with a time horizon of 10 years. Costs were calculated from the perspective of Korean healthcare, and health utility values were extracted from published sources. RESULTS: Based on data from the trial, the mean QALY in the ICS group was 7.16 compared to 10.8 in ICS followed by the HIPEC group. With an incremental QALY of 3.64, the ICS followed by HIPEC, was estimated to obtain an ICER of KRW 954,598 (USD 708.3) per QALY. CONCLUSION: The findings of the study suggest that ICS followed by HIPEC, is cost-effective with a significant gain in QALYs. These results may support the current reimbursement of HIPEC from Korean insurance services and the management of long-term conditions.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。